Cell capable of expressing exogenous GITR ligand
View Patent ↗Disclosed are: a cell capable of expressing an exogenous GITRL or an exogenous GITRL derivative; a method for producing the cell; a therapeutic or prophylactic agent comprising the cell as an active ingredient; use of the cell in the manufacture of a therapeutic or prophylactic agent; a method comprising a step of administering the cell to a subject; a viral vector carrying a gene encoding a GITRL or a GITRL derivative; a therapeutic or prophylactic agent comprising the viral vector as an active ingredient; use of the viral vector in the manufacture of a therapeutic or prophylactic agent; and a method comprising a step of administering the viral vector to a subject.
1. A virus vector comprising a nucleic acid encoding a fusion protein of a GITRL (Glucocorticoid-Induced Tumor necrosis factor Receptor Ligand) extracellular domain fragment and an Fc fragment of an immunoglobulin, wherein the Fc fragment is located at the C terminus of the fusion protein.
2. The virus vector of claim 1 , wherein said vector is selected from the group consisting of a retrovirus vector, an adenovirus vector, an adeno-associated virus vector and a Sendai virus vector.
3. A therapeutic or prophylactic agent comprising the virus vector of claim 1 as an active ingredient.
4. A therapeutic or prophylactic agent comprising the virus vector of claim 2 as an active ingredient.
5. A method for treating a subject with a tumor disease or an infectious disease, comprising administering a cell capable of expressing a fusion protein of a GITRL (Glucocorticoid-Induced Tumor necrosis factor Receptor Ligand) extracellular domain fragment and an Fc fragment of an immunoglobulin to said subject, wherein the Fc fragment is located at the C terminus of the fusion protein.
6. A method for treating a subject with a tumor disease or an infectious disease, comprising administering the virus vector of claim 1 to said subject.
7. A method for treating a subject with a tumor disease or an infectious disease, comprising administering the virus vector of claim 2 to said subject.